Floatz logo

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-

Inflammatory Breast Cancer

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Inflammatory Breast Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Hoffmann-La Roche
Phase 3BBB
Cyclophosphamide
Northwestern University
Phase 3BBB
Carboplatin
Northwestern University
Phase 3BBB
Docetaxel
Association Tunisienne de lutte Contre le Cancer
Phase 3BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:

acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemia with minimal differentiationDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →